Document Detail

The human pharmacology of thrombin inhibition.
MedLine Citation:
PMID:  9116934     Owner:  NLM     Status:  MEDLINE    
Heparin has an established place in the treatment of venous thrombosis. It is also effective in syndromes of arterial occlusion, such as unstable angina, although its benefit: risk ratio when combined with thrombolytic drugs in the treatment of myocardial infarction remains open to debate. Specific thrombin inhibitors have several theoretical advantages over heparin. However, they have failed to realize their promise in phase III trials, perhaps because of inadequacies in trial design. Our understanding of protease-activated receptors, such as that for thrombin, is modest and the comparative advantages of receptor antagonism versus specific thrombin inhibition are unknown. Increasing usage of low molecular weight heparins and glycoprotein IIb/IIIa antagonists provide a changing context for evaluation of these drugs. Problems in phase III clinical trials might be minimized by placing greater emphasis on dose finding in phase II.
G A FitzGerald
Related Documents :
9693784 - Calcitonin gene-related peptide immunoreactivity in the rat efferent vestibular system ...
9877154 - The cgrp receptor can couple via pertussis toxin sensitive and insensitive g proteins.
22370284 - Effect of a 5-ht(1a) receptor agonist (8-oh-dpat) on the external urethral sphincter ac...
8649224 - Specific potentiation by cyclic amp of natriuretic peptide-mediated cyclic gmp producti...
1327844 - Selective dopaminergic mechanism of dopamine and skf38393 stimulation of inositol phosp...
9466454 - Detailed mapping of serotonin 5-ht1b and 5-ht1d receptor messenger rna and ligand bindi...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Coronary artery disease     Volume:  7     ISSN:  0954-6928     ISO Abbreviation:  Coron. Artery Dis.     Publication Date:  1996 Dec 
Date Detail:
Created Date:  1997-04-24     Completed Date:  1997-04-24     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  9011445     Medline TA:  Coron Artery Dis     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  911-8     Citation Subset:  IM    
Center for Experimental Therapeutics, University of Pennsylvania, Philadelphia, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anticoagulants / pharmacology*
Antithrombins / administration & dosage,  pharmacology*
Blood Coagulation / drug effects*
Blood Platelets / drug effects*
Clinical Trials, Phase II as Topic
Clinical Trials, Phase III as Topic
Drug Delivery Systems
Heparin / pharmacology*
Reg. No./Substance:
0/Anticoagulants; 0/Antithrombins; 9005-49-6/Heparin
Erratum In:
Coron Artery Dis 1997 Jan;8(1):A4

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Enhancement of recombinant tissue-type plasminogen activator thrombolysis with a selective factor Xa...
Next Document:  Total costs of laparoscopic and lichtenstein inguinal hernia repairs: a randomized prospective study...